Tempus AI operates in the health information services industry, providing data-driven precision medicine solutions.
The company is a leader in leveraging artificial intelligence to analyze clinical and molecular data to personalize cancer care and improve patient outcomes.
更新时间:December 28, 2025, 16:00 EST
Based on a comprehensive analysis of TEM, the investment case appears highly speculative and carries substantial risk. The stock is not recommended for purchase at this time.
Technical Analysis & Valuation: TEM exhibits severe technical weakness, having declined sharply and underperformed the market significantly. Its valuation is particularly concerning, as negative earnings are paired with extremely high price-to-sales and price-to-book ratios, indicating severe overvaluation not supported by current fundamentals.
Fundamentals & Risk: Persistent unprofitability, negative cash flow, and a high debt load create fundamental vulnerability. This is compounded by extreme price volatility and significant downside risk, as evidenced by a maximum drawdown of over 58% in the past year.
Given the combination of weak price action, unsustainable valuation, poor financial health, and high risk, investors should avoid this position. A turnaround would require a substantial improvement in profitability and cash flow generation, which is not currently evident.
Based on the comprehensive analysis provided, the 12-month outlook for TEM is bearish and carries significant risk. Key catalysts for a potential turnaround would be a dramatic improvement in profitability and a clear path to positive cash flow generation, though neither is currently evident. The primary risks are its unsustainable valuation metrics, persistent unprofitability, negative cash flow, and high debt load, which could lead to further price declines. While the analyst target price of approximately $89 suggests significant theoretical upside, the underlying fundamental and technical weaknesses indicate this target is highly optimistic and unlikely to be achieved without a major positive shift in the company's operations. A prudent target price range would be considerably lower than the current price until fundamental health improves.
大多数华尔街分析师对TEM未来12个月的走势持乐观态度,主流目标价集中在$0.00左右,表明普遍预期公司仍有上涨空间。
综合来看,TEM具备一定的投资价值,但也面临多重挑战。以下是投资该股票前需要权衡的主要因素。
TEM has demonstrated extremely weak performance, experiencing substantial declines across multiple timeframes with severe underperformance versus the market.
Over the past month, TEM has declined 15.51% and has dropped 23.62% over three months, significantly underperforming the market by 28.02% during the latter period, indicating pronounced weakness. The stock's current price of $64.26 sits approximately 38% above its 52-week low, suggesting it remains closer to the lower end of its yearly range after the steep declines. Given the magnitude of the recent drop and its position relative to the 52-week high, TEM appears significantly oversold, though the substantial maximum drawdown of -58.37% highlights the exceptional volatility and downside risk present over the past year.
| 时间段 | TEM涨跌幅 | 标普500 |
|---|
Revenue & Profitability TEM's revenue grew 6.2% sequentially from Q2 to Q3 2025, reaching $334 million. However, profitability remains deeply challenged, with operating margins deteriorating to -17.9% and net margins at -23.9%. The gross margin of 61.6% is healthy, but high operating expenses are driving significant losses.
Financial Health The company maintains moderate liquidity with a current ratio of 3.28, though its debt position is concerning with a debt-to-equity ratio of 2.63 and total debt capitalization of 72.5%. Cash flow generation is problematic, with negative operating cash flow and a cash flow-to-debt ratio of -0.09, indicating difficulty servicing obligations.
Operational Efficiency Operational efficiency metrics are weak, with ROE at -15.7% and ROA at -3.5% reflecting poor capital utilization. Asset turnover of 0.15 suggests inefficient use of assets to generate revenue. The negative interest coverage ratio of -3.89 further indicates operational cash flows are insufficient to cover interest expenses.
Valuation Level: TEM's valuation metrics indicate significant overvaluation, marked by negative forward PE and EV/EBITDA ratios reflecting unprofitability. The extremely high price-to-book ratio of 22.5 and elevated price-to-sales ratio of 10.3 suggest investors are pricing in substantial future growth expectations that current fundamentals do not support. These ratios collectively point to a stock trading at premium multiples despite negative earnings and cash flow generation.
Peer Comparison: Without industry average data available, a formal peer comparison cannot be conducted. However, the negative earnings multiples and exceptionally high valuation ratios would typically deviate significantly from profitable industry norms. The absence of positive comparative metrics suggests TEM operates in a specialized or early-stage sector where conventional valuation benchmarks may not fully apply.
Volatility Risk: TEM exhibits extreme volatility risk, with a maximum drawdown of -58.37% over the past year indicating severe price erosion during market downturns. The absence of a published Beta is notable and may suggest insufficient trading history or data for reliable correlation analysis with the broader market, emphasizing the stock's speculative and potentially unpredictable nature. These factors combined point to a highly unstable investment susceptible to significant price swings.
Other Risks: The company faces moderate short interest at 4.59%, which reflects some skepticism in the market but does not indicate an imminent squeeze scenario. The lack of a Beta, however, raises concerns about potential liquidity issues or limited analyst coverage, which could exacerbate volatility and create challenges for entering or exiting positions. These factors contribute to an elevated overall risk profile beyond just price volatility.
Bearish. TEM appears significantly overvalued with negative earnings and poor profitability, while exhibiting extreme price volatility and high debt. This combination of weak fundamentals and high risk makes it unsuitable for most investors. It may only be considered by highly risk-tolerant speculators betting on its long-term AI potential, not by value or conservative investors.
Based on the provided data, TEM stock is significantly overvalued.
Its valuation metrics are exceptionally high, with a negative forward P/E (-136.7) confirming unprofitability and a Price-to-Book ratio (22.5) and Price-to-Sales ratio (10.3) that are extreme by almost any industry standard. These multiples indicate investors are pricing in massive future growth expectations that are not supported by the company's current fundamentals, which include steep losses, negative cash flow, and poor operational efficiency. The stock's price appears disconnected from its present financial reality.
Based on the provided information, here are the key risks of holding TEM stock, ordered by importance:
1. Severe Financial Distress: The company's deeply negative profitability, negative operating cash flow, and high debt load (72.5% debt capitalization) create a substantial risk of financial instability and an inability to meet its obligations. 2. Extreme Price Volatility: The stock's history of severe price erosion, including a maximum drawdown of -58.37%, indicates a high susceptibility to dramatic price swings, making it a highly speculative and unstable holding. 3. Persistent Operational Inefficiency: Consistently negative returns on equity and assets, combined with low asset turnover, demonstrate a fundamental weakness in the company's ability to profitably utilize its capital and operations. 4. Limited Market Liquidity and Data: The absence of a published Beta suggests potential illiquidity and a lack of analyst coverage, which can exacerbate volatility and make it difficult to enter or exit positions at desirable prices.
Based on the provided analysis, our forecast for TEM stock through 2026 is highly cautious. We project a base case target price significantly below the current $64.26, potentially in the $35-$45 range, with a bull case of $65-$75 contingent on a successful operational turnaround.
Key growth drivers necessary for any positive performance would be a dramatic reduction in operating expenses to achieve profitability, a return to positive operating cash flow to manage its high debt load, and improved asset turnover to justify its valuation.
Our main assumptions are that the company's fundamental weaknesses—specifically its persistent unprofitability and negative cash flow—will continue to pressure the stock in the near term, and that a meaningful recovery will be a multi-year process requiring significant operational changes.
This forecast carries high uncertainty, as it is entirely dependent on a management-led turnaround that is not yet evident; without decisive corrective action, the stock faces substantial downside risk.